Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC61 in advanced solid tumors
NCT05287399Phase 1Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Aug 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ASC61 in solid tumor (advanced stage) (6 arms), sponsored by Ascletis Pharma Inc. Primary endpoints: Dose-Limiting Toxicities at 28 days and Recommended Phase 2 Dose. Started Aug 2022; status: completed.
02
Drugs
ASC61
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05287399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05287399.